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ABSTRACT 
 
Medulloblastomas are the most commonly occurring group of malignant 
pediatric brain tumors. Over the years, these cerebellar tumors have been 
histologically and genetically classified to yield a number of distinct subtypes that 
confer differing disease progression and prognoses. Previous studies on the 
SHH medulloblastoma mouse model from Jackson-Grusby laboratory have 
revealed a cancer stem cell origin that may be responsible for the metastatic and 
more malignant fraction of this subtype. The lab worked with mice harboring 
mutations in tumor suppressor genes Ptch1 and p53. A novel discovery from this 
background was that mouse cerebellum deficient in p53 and heterozygous for 
the SHH pathway inhibitor gene Ptch1 developed an aberrant stem cell 
population predisposed to malignant progression through Ptch1 loss-of-
heterozygosity (LOH).  
To study this tumor initiating population of stem cells, the lab has 
constructed a Ptch1 heterozygous, p53 deficient mouse model which reliably 
provided mice with aberrant cerebellar stem cells (pre-LOH) and cancer stem 
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cells (post-LOH). Sox2, a neural stem cell marker and transcription factor for 
stem cell maintenance, has been indicated as a prospective marker to isolate 
these different Ptch1;p53 stem cells. To characterize the marker’s ability to 
detect the stemness of the differing SHH medulloblastoma stem cells, previous 
studies in the lab measured Sox2 antibody levels by inducing differentiation 
through growth factor withdrawal. The finding was that Sox2 levels were 
maintained in the cancer stem cell population, indicating a resistance to 
differentiation, while Sox2 levels dropped in the aberrant stem cell population, 
indicating the ability to differentiate. 
The current study aimed to test whether the results of the growth factor 
withdrawal experiment were also seen at the transcriptional level of Sox2. The 
study was conducted by inserting a Sox2-GFP transgene into the lab’s SHH 
medulloblastoma mouse model and measuring Sox2 transcriptional activity via 
GFP fluorescence. The results proposed a progressively heightened resistance 
to differentiation cues based on malignancy in which wild-type stem cells were 
least resistant, aberrant stem cells were weakly resistant, and cancer stem cells 
were strongly resistant. The Sox2 expression in cancer stem cells measured by 
GFP fluorescence confirmed the existence of a robustly Sox2 upregulated 
population. These strongly GFP+ cells absent in aberrant stem cells, justifies the 
strong stem-like characteristics associated with the malignant stem cell 
population. Specifically, the Sox2 expression is amplified by an auto-feedback 
loop between Sox2 and the SHH pathway to confer resistance to differentiation. 
 vi 
Altogether these results confirm the effectiveness of Sox2 in detecting the 
stemness of varying cerebellar stem cell types, proposing Sox2 as a reliable 
prospective marker for pre-malignant and malignant medulloblastoma stem cells. 
 vii 
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INTRODUCTION 
 
Medulloblastoma 
Medulloblastoma is the most common malignant brain tumor found in 
children, accounting for 25% to 30% of pediatric central nervous system tumors 
(1). Adult medulloblastomas occur rarely, and represent 4% to 6% of all primary 
adult intracranial malignancies (5). The tumor itself arises from the cerebellar 
vermis and forms lesions along the ventricles (6). As a result, medulloblastoma 
patients present with cerebellar symptoms that range from truncal ataxia, gait 
disturbances, and hydrocephalus. Lethargy, headache, and morning vomiting are 
also symptoms commonly observed (3). 
In 2007, medulloblastoma has been histopathologically categorized by the 
World Health Organization (WHO) into 5 different subtypes: classic, anaplastic, 
large cell, desmoplastic, and extensively nodular. Classic histology consists of 
round, hyperchromatic nuclei with little cytoplasm and high cell density. 
Anaplastic and large cell medulloblastomas are similar in that they have 
extensive mitotic and apoptotic characteristics while retaining undifferentiated cell 
types. The desmoplastic/nodular histology is characterized by nodules of 
reticulin-free zones surrounded by a dense fiber of reticulin containing 
proliferative cells. In extensively nodular medulloblastoma, neuropil-like tissue 
filled lobular architecture is the dominant morphology (2,3). For children, the 5-
year survival rate for medulloblastoma is, if properly treated, 70-80% with even 
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the most malignant WHO grade IV lesions (2,19). The treatment options include 
surgery, chemotherapy, and cranio-spinal radiotherapy. Despite the effectiveness 
of medulloblastoma treatments, most patients develop long-term side effects due 
to the toxicity of therapies like chemotherapy and radiotherapy. These side 
effects include developmental, neurological, neuroendocrine and psychosocial 
problems which severely depreciates the cognition and intellect of patients (1).  
Recently, advancements in molecular characterization through large scale 
transcriptional profiling of pediatric primary medulloblastomas has led to the 
identification of four subgroups: WNT, SHH, Group 3 and Group 4. (1,4). Similar 
studies into the gene expression data on adult medulloblastomas revealed a 
SHH subgroup majority, but in contrast to childhood medulloblastomas, no Group 
3 medulloblastomas were found (5).  
 
Cerebellar development of mouse 
The mammalian cerebellum is involved in numerous motor, sensory, and 
cognitive functions (20).  It is formed through a complex interplay of 
developmental signals (Figure 1). During the cerebellar development as well as 
the development and maintenance of the central nervous system (CNS), the 
undifferentiated neural epithelium goes through the process of carefully 
balancing neurogenesis with the maintenance of neural stem and progenitor 
cells. This is done via Notch1 signals as well as SoxB1 transcription factors, 
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which includes Sox1, 2, and 3, repressing proneural genes against differentiation 
proteins like Sox21 (26).  
The gross cerebellum first starts forming through the dorsal area of the 
hindbrain rhombomere 1 (rh1) by receiving signals from the isthmic  organizer 
and fourth ventricle roof plate (Figure 1a-1). The neurons found in the cerebellum 
are formed from two distinct embryonic germinal zones within the primordial or 
cerebellar anlage.  The two distinct zones, which are the rhombic lip and the 
cerebellar ventricular zone, form through an antagonistic balance between 
Notch1 and Bmp signals (8). Specifically, the rhombic lip is formed through Bmp 
downstream signals originating from the roof plate while Notch1 counters Bmp to 
form the cerebellar ventricular zone (Figure 1a-2). These two zones in turn can 
be marked by two distinct transcription factors. Ptf1a is a basic helix-loop-helix 
(bHLH) transcription factor found in the cerebellar ventricular zone. Ptf1a+ cells 
from this zone give rise to Purkinje, Golgi, basket, and stellate cells (Figure 1a-3). 
Dorsal to the ventricular zone is the rhombic lip which expresses a different 
bHLH transcription factor, Math1 (Figure 1a-4). Loss-of-function studies on 
Math1 showed that although Math1 isn’t required for the formation of the rhombic 
lip, they are required to generate all CGNPs  and consequently the EGL (7).  
There is a time-sensitive migratory pattern arising from the ventricular 
zone and the rhombic lip. The first is that the differentiating cells from the 
ventricular zone radially migrate within the anlage. Loss-of-function studies have 
determined that an absence of Ptf1a in the ventricular zone cells leads to the 
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failure in generating cerebellar Purkinje cells and GABAergic neurons which in 
turn leads to complete cerebellar agenesis.Cells from the rhombic lip migrate to 
the anlage that produces a continuously proliferating outer layer. Of these cells, 
the cerebellar granular neuronal precursors (CGNP) forming the external granule 
layer (EGL) are induced by Sonic Hedgehog (SHH) signals from the Purkinje 
cells of the anlage to proliferate (Figure 1b-5). Finally, there is an inward 
migration of EGL cells that form the internal granule layer (IGL) which together 
forms the mature cerebellum (Figure 1b-6).  
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Figure 1.  Schematic of mouse cerebellar neurogenesis.  (a) Depicted is a 
parasagital section through the midbrain/hindbrain region of an embryonic day 
12.5 neural tube. The hindbrain rhombomere 1 (rh1) forms the cerebellum by 
receiving signals from the isthmic organizer (IsO) and fourth ventricle roof plate 
(rp). Within the cerebellar cluster, there are two germinal zones, the rhombic lip 
(rl) and cerebellar ventricular zone (VZ), and they are distinguished by 
transcription factors Math1 and Ptf1a. The Math1  expressing glutamatergic 
progenitor cells from the rhombic lip spread out in waves, and feed into the 
rostral migratory stream (RLS). The RLS then gives rise to multiple brain stem 
precerebellar nuclei within the cerebellar anlage such as the pontine nuclei (pn). 
More importantly, the Math1 expressing progenitors generate cerebellar granule 
cells (GC) which will eventually form the external granule layer (EGL). The Ptf1a 
expressing progenitors from VZ spread out radially into the cerebellar anlage to 
give rise cerebellar interneurons and deep cerebellar nuclei (DCN). M: midbrain; 
aq: aqueduct (b) Depicted is a midsaggital section of a mouse cerebellum at 
birth. The Purkinje cell layer (PCL) underneath the EGL secretes Shh proteins 
which are picked up by EGL cells to drive granule cell expansion. As 
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differentiation occurs, EGL cells cut through the PCL to form the IGL. CPe: 
Choroid plexus (Adapted from 7). 
 
 
Sonic Hedgehog Signaling on Cerebellar Development 
The Hedgehog pathway is a critical developmental patterning pathway for 
a variety of tissues. In the cerebellum, the cerebellar granular neuronal 
precursors (CGNPs) proliferate and initiate migration from the EGL from about 
P8. The mature cerebellar shape, such as the fold pattern, and its overall 
function is critically dependent on this expansion phase of CGNPs. Because the 
Hedgehog pathway is essential for signaling the expansion of CGNPs, it is 
heavily responsible for proper cerebellar maturation. The developmental 
importance of this is signified by the fact that Ptc1-null mice do not survive 
embryogenesis with overgrown neural tubes that fail to close (12). Sonic 
hedgehog (Shh) secreted from Purkinje neurons bind to a 12 transmembrane 
receptor, Ptc1, which dissociates it from another transmembrane protein, 
Smoothened (smo), to disinhibit the Shh signaling pathway. Ultimately, the 
activation of the pathway leads to the separation of the Gli-SuFu complex to 
avoid Gli degradation. The released Gli family proteins such as Gli1 and Gli2 
then transcriptionally activate granule cell proliferation (Figure 1b & 2). At P21, 
the CGNPs will eventually move through the Purkinje cell network to reach the 
IGL and differentiate. Therefore by P21, normal mouse cerebellar development is 
considered complete (9).  
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Figure 2. Schematic of the sonic hedgehog signaling pathway in the 
primary cilium. (A) SHH pathway remains inactivated in the absence of Shh, In 
this scenario, Ptch will be located at the base of the cilium and acts as an 
inhibitor of Smo located in the cytoplasm. Gli is bound to Sufu which targets Gli 
for degradation. (B) When present, SHH will bind to Ptc1 which leads to a 
disinhibition of Smo. This leads to the separation of the Gli-SuFu complex. Gli will 
then act as a transcription factor to drive proliferative transcription of hedgehog 
target genes (Adopted from 10). 
 
 
 
Molecular categorization of medulloblastoma 
As mentioned earlier, there are four distinct molecular subtypes of 
medulloblastoma elucidated through their mRNA expression profiles. These 
groups are: Wnt, Shh, Group 3, and Group 4.  
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The WNT-subtype medulloblastomas are driven by CTNNB1 mutations 
which drive nuclear accumulation of β-catenin and present with classic histology. 
Patients with this subtype of medulloblastoma have the best prognosis with more 
than 95% of the patients surviving. Unfortunately, it is also the least incident 
tumor, accounting for only about 10% of all medulloblastoma cases. Recent 
mouse models of Ctnnb1 transgene with Trp53 -/- background were shown to 
develop latent classic medulloblastomas originating from the dorsal brainstem (1, 
11). 
The SHH-subtype medulloblostoma is driven by aberrant SHH-signaling 
largely through Ptch1 mutation and is responsible for the large-cell-anaplastic 
and desmoplastic presentations of medulloblastoma. The survival rate for 
patients with SHH medulloblastoma drops down to ~60-80%.  A bimodal age 
distribution of incidence is characteristic in these patients with the susceptibility 
arising mostly during infancy and adulthood but not during childhood.  
Group 3 medulloblastomas have the worst prognosis out of the four 
subtypes, and is caused by aberrant expression MYC which is a proto-oncogene. 
These medulloblastomas are strictly pediatric and 50% of the cases are shown to 
be metastatic upon diagnosis. Histologically, they are large-cell or anaplastic.  
Group 4 medulloblastomas is the most common subtype accounting for 
about 40% of the cases. The prognosis is similar to SHH-subtype 
medulloblastomas. The tumours show classic histology and about one in three 
patients present with metastases. Proto-oncogenes MYCN and cyclin-dependent 
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kinase 6 (CDK6) amplifications are what drive and distinguish Group 4 
medulloblastomas from the rest (1, 4, 11).  
With the emergence of molecular markers as powerful prognostic 
indicators of medulloblastomas, it is now possible to combine both molecular and 
histopathological stratification for new treatment plans. Around 50% of the SHH 
medulloblastoma subgroup, for example, uniquely present with a prominent 
desmoplastic and nodular histology. Even so, certain histological presentations 
like classic morphology are seen throughout all molecular subgroups and would 
not provide much information on its own. In contrast, though anaplastic and large 
cells are present in all four molecular subgroups, its prognostic value is 
preserved due to the undifferentiated and mitotic nature of the cell types 
correlating with aggressive tumor. For example, Group 3 tumors which most 
strongly represent anaplastic and large cell histology have the worst prognosis 
out of all medulloblastoma subtypes. Despite such indications, the anaplastic and 
large cell histology hasn’t yet been studied thoroughly for each molecular 
subgroup. Therefore, consolidating molecular and histopathological evaluation of 
medulloblastomas will allow for a more focused treatment plan through careful 
risk assessment, not only for prognostic fidelity but also for minimizing side 
effects (3, 4, 25). 
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SHH medulloblastoma mouse model 
 There has been great success in generating the SHH-subtype 
medulloblastoma mouse model. Ptch1 mutation as a cause of medulloblastomas 
was first brought to attention by Gorlin’s syndrome patients who exhibited an 
increased risk of developing medulloblastomas due to an inactivating mutation of 
Ptch1. This led to the development of the first SHH medulloblastoma mouse 
model heterozygous for Ptch1. However, mice that were heterozygous for this 
gene alone showed low penetrance and high latency in developing 
medulloblastomas (12). In 2001, it was observed that Ptch1 +/-; p53-null mice 
(from here on out referred to as Ptch1;p53) had a dramatic rise in 
medulloblastoma incidence to greater than 95% (13). P53 is an important tumor 
suppressor gene that encodes for the transcription factor, Trp53, which inhibits 
aberrant cell cycle and DNA damage by arresting the cell cycle itself or initiating 
apoptosis. Because of this, patients with germline TP53 mutations, such as Li-
Fraumeni syndrome patients, exhibit significantly elevated cancer susceptibility 
(14). 
 
Brain Cancer Stem Cells 
 Ever since the discovery of stem cells in the haematopoietic system, 
studies have been made trying to harvest the regenerative capacity that a stem 
cell therapy could offer. On the other hand, it has also brought into focus the 
possible role of stem cells in tumor formation. The multipotency of stem cells is 
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essential to the normal development of organs and tissues in the human body. 
Their self-renewability is equally important in creating a niche of cells that have 
the capacity to continually supply and replenish tissues of more committed cell 
fates.  However, if misregulated, the self-renewable nature of stem cells can turn 
on its biological system to result in tumorigenesis. The implications are quite 
problematic when considering such small population of freely self-renewing cells 
could result in the continuous seeding of tumors even upon treatment with 
conventional bulk cancer therapies such as chemotherapy or radiotherapy (15, 
16). To complicate matters further, there have been studies demonstrating how 
progenitor cells and differentiated cells could acquire stem-like tumorigenic 
capacities due to accumulated mutations in the stem cells that passed down. 
What this also implies is that it would be easier for stem cells, which already have 
self-renewal capacity, to become cancerous through dysregulation rather than 
having differentiated cells unlocking this potential (15). From these insights, the 
cancer stem cell (CSC) theory was born. 
When stem-like cells in brain tumors were discovered using CD133, a cell 
surface antigen, the potential for testing the CSC hypothesis on brain tumor 
arose. A study that eventually stemmed from this idea was the discovery that 
cancer stem cells in the brain could act as brain tumor initiating cells.  
Experiments were performed in which CD133+ cells were sorted and isolated 
from human glioblastomas and medulloblastomas. These cells as well as 
CD133- brain tumor cells were intracranially xenografted into mice brains and 
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histologically compared. It was found that CD133+ brain tumor cells recapitulated 
the heterogeneous patient tumor phenotype while CD133- cells failed to do so, 
indicating CD133 as a surface marker for neural stem cells (17). While 
discoveries such as this lend strong support to the CSC theory, it has also 
opened up the door to the possibility of discovering a potential hierarchy of 
diverse brain cancer stem cells. 
 
Medulloblastoma brain tumor cells of origin 
It has long been established that a subset of SHH subtype 
medulloblastomas are derived from the external granular layer of the cerebellum 
and is therefore thought to be caused by CGNP expansion (18). Indeed many 
studies regarding Shh-pathway mutagenesis in mouse models, such as those 
involving Ptc1, SuFu, and Smo show gene expression profiles that support 
CGNPs as prospective cells of origin (4).    
However there is no concrete explanation as to why these progenitor cells 
are able to become tumorigenic with stem-like characteristics when they are 
supposedly limited in self-renewal and pluripotency. The fact that there is SHH 
medulloblastoma incidence for older children and adults who should have 
depleted their GCPs further highlights this perplexity, and this brought into 
question whether or not these are true cells of origin (18). As previously 
discussed, this could be the result of GCPs acquiring a de novo mutation that 
imbues stem-like properties. But it is also likely that there is a population of 
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aberrant neural stem cells propagating tumorigenesis. Certainly, comparisons 
between P5 and P7 Ptch +/- medulloblastoma gene expression profiles yielded 
two distinct profiles consistent with this notion. The fact that P5 SHH tumor, 
which is suggestive of stem cell origin, was highly metastatic while P7 tumors, 
suggestive of CGNP origin, remained nonmetastatic furthers the validity of this 
claim (27). 
 
Ptch1 Loss of Heterozygosity and Sox2 expression  
 Unpublished studies done by ChieYu Lin at Jackson-Grusby’s laboratory 
have suggested that contrary to the two-hit tumor suppressor model in which the 
first-hit is largely benign, Ptch1 works synergistically with p53 to increase SHH 
medulloblastoma incidence. Upon loss of heterozygosity (LOH) of Ptch1, the pre-
malignant cells transform into a stem-like metastatic tumor-initiating population. 
Sox2, an important transcription factor in the maintenance of stem cell identity 
(28), is vital in the explanation of this observation. Under in vitro growth factor 
withdrawal experiments, epidermal growth factors (EGF) and basic fibroblast 
growth factors (bFGF) that maintain Sox2 expression are removed from culture. 
In this experiment, the aforementioned tumor-initiating population is thought to be 
able to resist differentiation seen in wild-type cerebellar stem cells under the 
same condition. This is because Gli2, the downstream effector of the SHH 
pathway, enhances Sox2 expression while Sox2 also upregulates Shh, creating 
an auto-feedback loop. The tumor-initiating population is able to resist 
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differentiation due to the loss of Ptch1, the inhibitor of SHH pathway, feeding the 
auto-feedback loop of Sox2 expression to maintain stem cell identity (22,23). 
This highly stem-like tumor-initiating population could therefore retain its 
stemness and seed metastatic SHH medulloblastomas.  
 
Specific Aims and Objectives 
The broad research objective of this study is to determine if the level of 
GFP expressed by the Sox2-GFP reporter transgene represents the self-
renewability of isolated cerebellar cell populations. In other words, the 
overarching goal is to establish a correlation between Sox2 expression and the 
stemness of the cerebellar cells. The outcome will determine whether or not 
Sox2 can be reliably used as a prospective marker for isolating a previously 
unappreciated cancer stem cell population. This population could be the potential 
cellular origin of SHH medulloblastomas in Ptch1;p53 mice..  
One way to characterize Sox2 as a marker is to compare the different 
populations of cerebellar cells, particularly the aberrant stem cells and tumor 
stem cells, under growth factor withdrawal conditions. Growth factors EGF and 
bFGF are thought to maintain Sox2 expression by supporting the maintenance of 
stem cell signaling pathways. Once growth factors are removed, stem cells are 
unable to maintain their stemness and differentiate. 
Preliminary in vitro studies from Jackson-Grusby laboratory suggested 
diminished Sox2 levels upon growth factor removal for 3-week Ptch1;p53 mice 
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while the same conditions had little effect on Ptch1;p53 tumor Sox2 levels.This 
proposes that 3-week Ptch1;p53 cells maintain their ability to respond to 
differentiation cues while Ptch1;p53 tumors resist them. However, this study was 
done using antibody staining to quantify Sox2 protein levels, and as a 
consequence lacked the ability to measure Sox2 expression levels. Therefore the 
aim of this study is to acquire a higher fidelity measurement of Sox2 expression 
through a Sox2-GFP transgene mouse model to confirm Sox2 as a functional 
marker for cerebellar tumor initiating cells.   
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MATERIALS AND METHODS 
 
Production of mouse chimeras and animal husbandry 
Mice harboring the Sox2-GFP reporter were constructed using conventional ES 
cell technology and crossed to Ptch1;p53 breeding mice. These mice were 
maintained in pathogen-free conditions at Boston Children’s Hospital and 
procedures were performed following approval by the Institutional Animal Care 
and Use (IACUC). 
 
Media 
Neurosphere media was used to culture cerebellar neurospheres. The 
media has been optimized for growing and culturing cerebellar stem cells. It 
contains Dulbecco's Modified Eagle Medium/Ham’s F-12 (DMEM/F12), basic 
fibroblast growth factor (bFGF; 20ng/ml), epidermal growth factor (EGF; 
20ng/ml), B27 supplement, and penicillin/streptomycin. 
 
Cell isolation from animal tissue 
Whole mice cerebellums were individually excised and manually minced 
with a blade on 100µl NS media. The cells were collected in a 15ml conical vial in 
2ml of NS media and dissociated through mechanical trituration media to obtain 
single cell suspension.  
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Bulk Culture 
5% by volume of the mechanically triturated cerebellum in NS media was 
plated on to a 60mm petri dish containing 6ml NS media. Passaging of bulk 
cultures was done by spinning down cell suspension, aspirating media, and 
mechanically triturating the pellet in 2ml NS media to achieve single cell 
suspension. Cells were kept in the 37C incubator.  
 
Cell lines 
4 different cell lines were selected for the growth factor removal 
experiment. The P7 WT Sox2-GFP represents a WT cerebellar stem cell 
population while the non-transgenic P7 WT (-) Sox2-GFP provides a negative 
control for GFP expression. The 3-week Ptch1;p53 Sox2-GFP will help study the 
experimental effects on the aberrant stem cell population while the Ptch1;p53 
Sox2-GFP tumors can be used as a model SHH tumor stem cell line. Bulk 
cultures from these representative cell lines were maintained through several 
passages until ready for growth factor removal study (Table 1). 
 
Table 1. List of cell lines used and their passage history. The number of days 
indicates how long the cells were in each suspension before passaging. 
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Growth factor withdrawal 
 Cells for the growth factor removal experiment were prepared first by 
genotyping the mice in advance to select desired cell lines. The mice used are 
outlined in Table 1. The triturated cerebellums were each passaged into bulk 
neurosphere cultures. Cells were then maintained in NS media through regular 
passaging until ready for growth factor withdrawal. Cultures were visually 
confirmed to be fluorescent under the GFP scope before initiating growth factor 
experiment. A fraction of each bulk culture was FACS analyzed at 0hrs. The rest 
of each culture was triturated and equal volumes were split into a 15ml conical 
vial. Both control group suspensions were spun down at 1000rpm for 5 minutes. 
Supernatants were aspirated and pellets were resuspended with either the 
growth factor (+) or the growth factor (-) NS media and centrifuged again as a 
wash step. Finally, the growth factor (+) and (–) cell suspensions were each 
respectively plated on 60mm petri dishes containing 6ml NS media with or 
without EGF and bFGF. The cells were then kept in the 37C incubator for 48 
hours until ready for FACS analysis (Figure 3).  
 
Flow cytometry 
The cerebellar cells were isolated as described above. The cells were 
then resuspended in FACS buffer, which contains PBS + 2mM EDTA + 0.5% 
BSA, and centrifuged at 1,000rpm for 5 minutes to wash. The cells were 
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resuspended in FACS buffer and pipetted through a BD 70 µl cell strainer. Cells 
were then put on ice until analyzed using a BD LSRII system. 
Compensation control was performed using a 121022 P7 WT (-) Sox2-
GFP as a negative GFP/unstained control and 120904 Ptch1;p53 Tumor as 
positive GFP control. To exclude dead cells and debris that inevitably accompany 
whole cerebellar suspensions, the samples were stained with 7AAD (BD 
Biosciences) live-dead stain and gated against using forward scatter (FSC)/side 
scatter (SSC) parameters.  
Post-flow cytometry analyses were performed on FlowJo (Tree Star). The 
program was also used to generate graphs, histograms, and calculate geometric 
means. FACS analysis experiments were done at HSCI/Joslin Flow Cytometry 
Core. 
 
 
Genotyping 
Genomic DNAs of mice were obtained by clipping the mice toes at P4-5 for P7 
WT mice, P14 for 3-week Ptch1;P53 mice, and P21 for the medulloblastoma 
mice. The clipped tails were then lysed overnight in lysis buffer + Proteinase K. 
Genomic DNA was extracted from lysate using standard isopropanol precipitation 
protocol, and PCR analyzed. 
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RESULTS 
 At 48 hours of growth factor withdrawal, the only cell line to show a robust 
GFP fluorescent population was the Ptch1;p53 tumor line at both (+) and (–) 
growth factor conditions (Figure 4). This was perplexing since the P7 WT and 3-
week Ptch1;p53 bulk cultures contained cerebellar stem cell populations that 
should be maintaining Sox2 expression, especially in (+) growth factor NS media.  
 
 
Figure 3. Experimental outline of the 48 hour growth factor withdrawal.      
3-week Ptch1;p53 Sox2-GFP, Ptch1;p53 Sox2-GFP tumor, and P7 Ptch1;P53 
Sox2-GFP cerebellums were put in bulk culture, passaged regularly, and 
analyzed before and after 48hr GF withdrawal. 
 
 21 
The cell line genotypes were confirmed with PCR genotyping results of 
mice tail lysates (Not shown). Also, the cultures were visually confirmed to exhibit 
GFP fluorescence before splitting into growth factor withdrawal treatment groups 
(not shown). Furthermore, all cell lines were confirmed to be confluent with 
neurospheres for each passage leading up to the experiment. The fact that 
genotypically confirmed Sox2 expressing single cell suspensions were expanding 
into neurospheres supports the expectation that there are stem-like cells within 
the culture. With the confidence that there are GFP expressing stem cells 
represented in the result, alternate means of measuring this population was 
necessary. 
 
GFP fluorescence histogram reveals distinguishable Sox2-expressing 
populations 
 Analyzing the histogram representation of the GFP fluorescence FACS 
plot provided a competent way of measuring heterogeneous GFP intensities and 
yielded a surprising discovery on the nature of Sox2 expression. Comparing the 
GFP fluorescence of the live cell population for P7 WT and 3W Ptch1;p53 under 
growth factor (+) vs (-) conditions, it was apparent that there is a binary 
distribution of GFP fluorescence intensity (Figure 5). While P7 WT with growth 
factors show an appreciable intermediate level of Sox2 expressing population as 
well as a low/non-GFP expressing population, the same cell line without growth 
factors completely lacks the intermediate level population. This suggests that the 
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removal of growth factors prompted cellular differentiation or apoptosis of the WT 
  
 
Figure 4. 48hour growth factor withdrawal FACS analysis of GFP 
fluorescence. Side-by-side comparison of P7 WT, 3W Ptch1;p53, and 
Ptch1;p53 Tumor under GF(+) and (-) conditions. The graphs represent a 
spectrum of live cells and their GFP intensity plotted against SSC. The plots have 
been preliminarily GFP+ gated to visualize strongly GFP expressing cells.  
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stem cells within the bulk culture. In comparison, the 3W Ptch1;p53, while similar 
in pattern to the P7 WT, displays a smaller but clear GFP peak under growth 
factor withdrawal condition. This could indicate that while the aberrant stem cell 
population retains differentiation capacity, there is subpopulation of these stem 
cells that might be resistant to differentiation cues or apoptosis upon growth 
factor removal. 
 
 
Figure 5. 48 hour growth factor withdrawal GFP fluorescence intensity 
histogram. Side-by-side comparison of P7 WT, 3W Ptch1;p53, and Ptch1;p53 
Tumor under GF(+) and (-) conditions. The graphs represent the GFP 
fluorescence intensity of live analyzed cell. 
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Confirming heterogeneity of Sox2-expressing populations 
 To confirm that the separation of fluorescence peaks represent two 
distinct population of cells instead of artifacts, the geometric means of the 
intermediate GFP and low GFP intensity peaks from the 3-week Ptch1;p53 cells 
were compared (Figure 6). There was over a 7-fold increase in the geometric  
 
 
Figure 6. 3W Ptch1;p53 geometric mean comparison of GFP fluorescence 
intensity between intermediate and low GFP expressing populations. 
 
mean of the intermediate GFP relative to the low GFP fluorescence intensity for 
the 3-week Ptch1;p53 cells with growth factor. There was also a near 10-fold 
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increase in geometric mean for 3-week Ptch1;p53 cells without growth factor. 
The high magnitude separation between the mean GFP fluorescence intensities 
suggests that there are indeed two distinctly heterogeneous populations of cells 
differentiated by their GFP fluorescence. 
 
Aberrant stem cells retain differentiation capacity 
 As mentioned earlier, there was a visible drop of GFP producing 3-week  
 
 
Figure 7. 48 hour growth factor withdrawal GFP fluorescence intensity 
distribution of 3W Ptch1;p53 cells. The percent total population distribution of 
low and intermediate GFP fluorescent cells determined by categorizing GFP 
intensity peaks in the histogram (shown in Figure 5). 
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Ptch1;p53 cells upon growth factor removal. As a measure of % total population, 
intermediate GFP expressing cells dropped nearly 30% in growth factor (-) cells 
compared to (+) cells, suggesting that Sox2 expression is diminished upon 
growth factor removal (Figure 7). This reduction in expression is consistent with 
the fact that growth factor withdrawal cues cerebellar stem cells to differentiate. 
Thus, the detection of decreased Sox2 expression in the treatment group 
coinciding with the decreased stem cell population lends further support to the 
idea that the Sox2 markers can identify potential medulloblastoma-initiating stem 
cells. Further, this would also indicate that aberrant stem cells yet retain 
differentiation capacity although perhaps to a lesser degree than P7 WT.  
  
Ptch1;p53 tumor shows triphasic Sox2 expression pattern and a robustly 
Sox2 expressing population 
 The most surprising discovery of this study came from analyzing the GFP 
fluorescence histogram of the SHH medulloblastoma treatment group (Figure 5). 
This is due to the clear demonstration of multiple Sox2 steady state expressions 
observed between the tumor with and without growth factor. For the (+) growth 
factor condition, along with the intermediately GFP expressing population there is 
a strongly GFP expressing population not found in other cell lines. Upon 
withdrawal of growth factors there’s a clear shift of fluorescence from the robustly 
GFP expressing cells to the to the intermediate GFP expressing cells and to a 
large population of low/non-GFP expressing cells (Figure 8). The original 
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prediction that SHH medulloblastoma tumor stem cells are resistant to 
differentiation cues is partially validated by the persistence of an intermediate 
and robust GFP expressing population (>60% of the total population) even after 
growth factor withdrawal.  
 
 
Figure 8. 48 hour growth factor withdrawal GFP fluorescence intensity 
distribution of Ptch1;p53 tumor cells. The percent total population distribution 
of low, intermediate, and high GFP fluorescent cells determined by categorizing 
GFP intensity peaks in the histogram (Figure 5) 
 
A clear triphasic Sox2 expression pattern also set the tumor GFP 
histogram apart from the other cell lines. The main indication for this pattern is 
 28 
that Sox2 expression isn’t binary. Rather, it would be appropriate to view Sox2 
expression as displaying multiple steady states. 
Lastly, another unique feature of the tumor stem cells is the presence of a 
robustly GFP expressing population. The strength of the GFP signal suggests 
that there might be an amplification of Sox2 expression. Certainly, recent studies 
have revealed that Gli2, the downstream effector of SHH pathway, binds to an 
enhancer that is vital for Sox2 expression (22). Studies done on hippocampal 
development proposed that Sox2 itself targets Shh as an agonist as well, 
bringing the causal relationship around full loop (23). This means that Sox2 
would be strongly upregulated in an auto-feedback loop involving the SHH 
pathway. There is no surprise then that the tumor cells, with highly activated SHH 
pathway due to ptch1 LOH, would have a robust GFP signal that is absent in 
other cell lines.  
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DISCUSSION 
 
 
 The results of this study show the effect of growth factor withdrawal on the 
Sox2 expression of three representative stem cell populations: WT P7 for the 
wild-type cerebellar stem cell population, 3-week Ptch1;p53 for the aberrant stem 
cell population, and Ptch1;p53 tumor for the cancer stem cell population.  
 The original question of whether or not aberrant stem cells retain 
differentiation capacity while tumor stem cells resist them, has yielded surprising 
discoveries on the nature of Sox2 expression and possible implications for the 
stemness of each tested population.  
First of all, the experiments revealed that the potential tumor initiating 
stem cells, rather than exhibiting an on/off Sox2 expression, displayed a 
fluctuation of Sox2 expressing steady states. The most robustly GFP fluorescent 
population not present in the other two cell lines demonstrated a possible 
interplay between Sox2 and the SHH pathway in which Ptch1 LOH ramps up the 
SHH pathway signaling. Sox2 expression is increased by upregulated Gli, the 
downstream effector of the SHH pathway, and Sox2 feeds back into the SHH 
pathway by upregulating Shh expression. This potential auto-feedback loop 
explains the highly proliferative nature of SHH tumor stem cells and may partially 
explain the reason for their malignant nature when compared to the yet pre-
malignant Ptch1;p53 stem cells. The auto-feedback loop also explains why the 
tumor stem cells seem relatively resistant to differentiation cues upon growth 
factor withdrawal. The clinical implication of this finding is that upon LOH, 
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Ptch1;p53 tumor stem cells may act as robust cerebellar tumors that have the 
ability to retain their stem-like state to confer metastasis. 
The study also confirmed the aberrant stem cell population’s ability to 
retain differentiation capacity, as made evident by the large drop in Sox2 
expressing cells upon removal of growth factors. Compared to the wild-type stem 
cell population which seemed to have completely lost Sox2 expressing cells 
under (-) growth factor condition, the aberrant stem cell population could be seen 
settling to a lower Sox2 expressing steady state. This relative resistance to 
differentiation cues could also be explained by Ptch1 heterozyogisty, which 
would upregulate SHH pathway that could potentially feed into the Sox2 auto-
feedback loop. Compared to the tumor stem cells with LOH though, this yet 
haplo-insufficient population would have a relatively weaker upregulation of the 
SHH pathway and therefore weaker resistance to differentiation cues. 
Put together, the growth factor withdrawal experiments implicate Sox2 as 
a reliable marker for determining the stemness of different cerebellar stem cell 
populations. Additional characterization studies of Sox2 will help establish it 
further as a prospective marker for isolating tumor initiating stem cells, and in so 
doing, it could solidify this aberrant stem cell population as the true cell origins of 
SHH medulloblastoma. However, in order to ascertain the relevance of the 
experimental outcome, it is important to discuss some of the issues with the data 
attained.  
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Figure 9. 48 hour growth factor withdrawal FACS analysis of live cell 
population. Side-by-side comparison of P7 WT, 3W Ptch1;p53, and Ptch1;p53 
Tumor under GF(+) and (-) conditions. The plot shows the subset of FSC vs SSC 
cells that were stained with a with live-dead stain. The gating indicates a 
conservative live cell gate. The numbers shown on the top left corner for each 
graph is the percentage of total FSC vs SSC subset that that are live cells 
according to the gating. 
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One potential problem with interpreting the experimental data stems from 
the fact that the observed cells had a high cell death ratio (Figure 9). What’s 
perplexing about this was that there was an extremely high cell death rate for all 
cultures regardless of growth factor conditions. Such a global increase in cell 
death implies a problem with the cell preparation. It is entirely possible that the 
mechanical trituration was too harsh, causing cells to rupture. The issue with this 
large dead cell population is that it could potentially skew the experimental data. 
Because it is uncertain what the exact cause of cell death is, it’s impossible to 
say whether the cell death was indiscriminate or targeting a particular group 
within the culture.  
To minimize cell death, some modifications were made to subsequent 
experiments. Namely, cells were triturated more gently and growth factor removal 
experiments were performed by allowing a 24hr post-passaging recovery for cells 
before splitting them into (+) & (-) growth factor media. Also, cells were passaged 
more regularly to keep them healthier and avoid overgrowth. 
 An encouraging piece of data from the live cell analysis is the fact that 
Ptch1;p53 tumor shows a predicted cell death pattern between (+) and (-) growth 
factor conditions (63.2% live cells and 28.7% live cells, respectively; Figure 9). A 
recent publication has proved that Sox2 directly upregulates Survivin, an inhibitor 
of the mitochondria-dependent apoptotic pathway in NSCs (24). Without a 
compensatory mechanism, decreased Sox2 expression would therefore lead to 
cell apoptosis. Because growth factors seem to be required for proper 
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maintenance of Sox2 expression, it makes logical sense that the Ptch1;p53 
tumors without growth factors have a drastic drop in cell survival due to 
decreased Survivin.   
 Another problem that has the potential to skew the experimental data lies 
in the number of events analyzed per sample on the LSR. For example, the 
number of cells analyzed for its GFP fluorescence in the 3-week Ptch1;p53 (+) 
growth factor condition was a mere 3,500 (Figure 4). The scientific standard for 
FACS requires ~20,000 cells to be analyzed for drawing a meaningful 
conclusion. Thus, with a small sample size, it is difficult to tell if the fluorescence 
pattern observed is a true representation of the actual Sox2 expression profile. 
Similarly, it is impossible to make statistical significance calculations due to the 
fact that only one experiment was performed per sample. Altogether,the scarcity 
of experiments gives less confidence to the data. Therefore, careful planning in 
subsequent experiments to ensure an adequate number of biological replicates 
(n=3) as well as sufficient cell numbers for each sample would allow the 
derivation of a meaningful experimental outcome with more confidence. 
 Lastly, the experiment could be set up in the future to allow for more 
prolonged growth factor removal time points. The decision to experiment with the 
48 hour time point was largely due to two factors. First, as shown above, there 
was significant cell death. The study would have required a very large cell 
population just to be able to have enough cells for an adequate sample size. But 
even if this was done, the fraction of dead cells would hinder interpreting the 
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experimental results. Secondly, the kinetics of the Sox2 transcriptional response 
is yet largely unknown. This means that the changes observed in GFP 
fluorescence could be occurring very quickly and therefore require a shorter 
rather than longer time point of observation. Such reasoning is complicated by 
the fact that GFP stability is also unknown. If the GFP is very stable, one could 
expect a slower Sox2 transcriptional response while a shorter half-life GFP would 
result in quicker Sox2 transcriptional action in response to growth factor 
withdrawal. Because of this transcriptional uncertainty, it is worth looking into 
different ways of preserving cell survival for longer withdrawal time points. 
Previous growth factor withdrawal studies were done with substrates (poly-L-
lysine coated wells) that cells could adhere to and differentiate. By facilitating 
differentiation under (-) growth factor conditions, it might be possible to increase 
the survival of cells that might otherwise be unable to differentiate and die as a 
consequence 
   
Future Direction  
 The limitation of using bulk cultures for doing growth factor removal 
studies is that there is a heterogeneous mixture of cell types within the culture. 
As seen with the Ptch1;p53 tumor stem cells, Sox2 expression seems to exhibit 
varying steady states. Yet without isolating a homogenous group from the 
heterogeneous mixture it is impossible to tell whether the cells are locked into 
expressing a certain steady state level of GFP. In other words, it cannot be said 
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whether the aberrant stem cells and tumor stem cells have a stochastic Sox2 
expression level that will fluctuate at any given time or if highly Sox2 expressing 
cells will always remain robustly Sox2 expressing. In light of results indicating a 
triphasic Sox2 expression level, it will be interesting to see if the isolated robustly 
GFP fluorescent population can regenerate the intermediate and low GFP 
fluorescent populations.  
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